Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Gyre Therapeutics's 3-Year RORE % for the quarter that ended in Mar. 2026 was -87.53%.
The industry rank for Gyre Therapeutics's 3-Year RORE % or its related term are showing as below:
GYRE's 3-Year RORE % is ranked worse than 92.93% of 1287
companies
in the Biotechnology industry
Industry Median: -11.53
vs GYRE: -87.53
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Gyre Therapeutics 3-Year RORE % Related Terms
Gyre Therapeutics 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Gyre Therapeutics's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Gyre Therapeutics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gyre Therapeutics 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Gyre Therapeutics's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Gyre Therapeutics (GYRE) has a 3-Year RORE % of -87.53 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Gyre Therapeutics and its competitors. According to the industry distribution chart, Gyre Therapeutics ranks #1196 out of 1287 companies in the Biotechnology industry, placing it in the top 92.9%.
Is Gyre Therapeutics' 3-Year RORE % too high?
Gyre Therapeutics' current 3-Year RORE % is -87.53. Based on the distribution chart, Gyre Therapeutics ranks #1196 out of 1287 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Gyre Therapeutics has a GF Score™ of 43/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' 3-Year RORE % compare to RLMD and ACRS?
According to the Biotechnology industry distribution chart, Gyre Therapeutics ranks #1196 out of 1287 companies for 3-Year RORE %. This places Gyre Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Gyre Therapeutics and its competitors. Gyre Therapeutics's current 3-Year RORE % is -87.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.81, compared to a current price of $6.86 — trading 30.1% below its estimated fair value. The current 3-Year RORE % is -87.53. Gyre Therapeutics' overall GF Score™ is 43/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current 3-Year RORE % is -87.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gyre Therapeutics (GYRE) Overvalued in 2026?
Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued.
The current stock price of $6.86 is trading 30.1% below its estimated GF Value™ of $9.81.
GuruFocus considers Gyre Therapeutics to be Significantly Undervalued.
Key valuation signals for GYRE:
3-Year RORE %: -87.53
GF Value™: $9.81 vs. price of $6.86 (30.1% below fair value)
No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
43GF Score
Get the complete analysis for GYRE
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GYRE has been successfully added to your 
